RE:RE:RE:RE:RE:RE:Theralase Hiring New IR Coordinator No matter who's hired, they won't be able to say more than what's public. So some should lower their expectations.
Clinical data is what will move this stock. The MD&A and corporate presentation give us enough additional and perspectives to know the direction where we're heading (NMIBC, COVID-19, NSCLC). The rest is about execution, with priority #1 to NMIBC.
Given that the Feb. 7 corporate presentation first introduced that notion of commercialization revenues, the fact that they've been identified for Jan. 2023, just after the late 2022 Breakthrough designation milestone confirms that a deal is sealed, conditional to such designation. Remember that big pharmas plan years in advanced.